As 2012 draws to a close, the two most impactful reforms China has set in motion within the healthcare space are the ongoing expansion of the country’s insurance plan and attempts to reform its hospitals.  The latter is one of the more complex and multi-faceted aspects of China’s overarching objectives as part of its 2009 [...]

In a recent CNBC column, I offered a glimpse into the promise and peril within China’s pharmaceutical space.  Without question, the market opportunity in China is enormous; however, the challenge of paying for drugs is more acute within the country than perhaps any other emerging economy (with the possible exception of India) purely because of [...]

Calling a market like China’s “emerging” is starting to come across as quaint – if not slightly paternalistic; after all, the country is some thirty years into an impressive set of economic changes that has jump started its once beleaguered economy.  Yet, for multinational pharmaceuticals working in China, the shifting sands that constitute selling into, [...]

Nowhere in the world is the dual healthcare challenge of price control and expanded coverage more clear than in China.  The human need for expanded coverage is acute; yet, finding policies that will empower industry to meet these challenges many times run at cross-purposes with the short-term cost containment objectives of government planners.  Some western [...]

While coming into Shanghai this afternoon, Saturday’s copy of the Shanghai Daily caught my attention.  One of the front-page national stories called out “TAINTED CAPSULES.”  The story pointed out that “In the latest round of medical capsule inspections, 204 batches made by 56 pharmaceutical enterprises across the nation were found to contain excessive chromium.”  This [...]

Thursday’s NextLevel Pharma conference spent a good portion of the day focused on China, both from a regulatory and market access point of view.  Given all that has been happening with healthcare reform in China, Thursday’s event was particularly helpful for those in the pharmaceutical and medical device industries who are attempting to “ride the [...]

From today’s Asia Times, my column on how the Anhui pharma model is spreading throughout the country and whether it might impact China’s medical device and diagnostic sectors as well.  The article can be read by clicking here, and is quoted below from Asia Times: Anhui medicine wrong for China By Benjamin A Shobert Few [...]

If you are looking to sell into, raise capital from, or identify partners for your healthcare business in China, then you owe it to yourself to add OneMedPlace’s China Forum to your list of future conferences to attend.  In a market as dynamic as China, with the sort of volatility one must expect when working [...]